Literature DB >> 1834370

Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population.

J Heinrich1, M Sandkamp, R Kokott, H Schulte, G Assmann.   

Abstract

In the Prospective Cardiovascular Münster (PROCAM) study, serum lipoprotein(a) [Lp(a)] and its relationship to pro- and anticoagulatory as well as fibrinolytic indices were determined in a large group of employees: 864 men (m) and 373 women (f), ages 16-65 years. Univariate statistical analysis showed Lp(a) concentration to be associated with fibrinogen concentrations in both sexes (m: r = 0.08, P less than 0.05; f: r = 0.20, P less than 0.001), but not with euglobulin fibrinolysis activity, tissue-type plasminogen activator, plasminogen activator inhibitor type 1 (PAI-1), or the split products of cross-linked fibrin (d-dimer). In women only, Lp(a) was significantly correlated with antithrombin III (r = 0.15, P less than 0.01) and Protein C (r = 0.17, P less than 0.01). Further sex-related differences were seen in the relationship between Lp(a) and age (m: r = 0.05; f: r = 0.23, P less than 0.001) and body mass index (m: r = 0.01; f: r = 0.19, P less than 0.001), primarily as a consequence of remarkable differences of Lp(a) concentrations between postmenopausal (mean = 79.4 mg/L) and premenopausal women (mean = 51.5 mg/L, P = 0.001). Multiple-regression analysis demonstrated a significant negative correlation of Lp(a) to PAI-1 (m: beta = -0.12, P less than 0.01; f: beta = -0.14, P less than 0.05) and a positive correlation to cholesterol (m: beta = 0.18, P less than 0.001; f: beta = 0.17, P less than 0.01) and systolic blood pressure (m: beta = 0.08, P less than 0.05; f: beta = 0.11, P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834370

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

2.  Clinical chemistry through Clinical Chemistry: a journal timeline.

Authors:  Robert Rej
Journal:  Clin Chem       Date:  2004-12       Impact factor: 8.327

3.  Surgical menopause versus natural menopause and cardio-metabolic disturbances: A 12-year population-based cohort study.

Authors:  M Farahmand; F Ramezani Tehrani; M Bahri Khomami; M Noroozzadeh; F Azizi
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

Review 4.  Cardiovascular pharmacology of hormone replacement therapy.

Authors:  G M Rosano; G Panina
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

5.  Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk.

Authors:  D J Byrne; I A Jagroop; H E Montgomery; M Thomas; D P Mikhailidis; N G Milton; A F Winder
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

6.  High lipoprotein (a) levels as a thrombogenic risk factor in Behçet's disease.

Authors:  A Orem; O Değer; O Memiş; K Calişkan; G Cimşit
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

7.  Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus.

Authors:  A Gaw; E Boerwinkle; J C Cohen; H H Hobbs
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation.

Authors:  Carol A Derby; Sybil L Crawford; Richard C Pasternak; Maryfran Sowers; Barbara Sternfeld; Karen A Matthews
Journal:  Am J Epidemiol       Date:  2009-04-08       Impact factor: 4.897

9.  Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population.

Authors:  A Steinmetz; A Kirklies; G Schlosser; W Cassel; J H Peter; K Ehlenz; J R Schäfer; P V Wichert; H Kaffarnik
Journal:  Clin Investig       Date:  1993-02

Review 10.  Hormone replacement therapy and the cardiovascular system. Nonlipid effects.

Authors:  J C Stevenson; D Crook; I F Godsland; P Collins; M I Whitehead
Journal:  Drugs       Date:  1994       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.